Public Profile

Halozyme Therapeutics, Inc.

Halozyme Therapeutics, Inc., a leading biotechnology company headquartered in the United States, has been at the forefront of innovative drug delivery solutions since its founding in 1998. Specialising in the development of enzyme-based therapies, Halozyme focuses on enhancing the efficacy of biologic drugs through its proprietary Hylenex® recombinant technology, which facilitates the subcutaneous delivery of therapeutics. With a strong presence in the biopharmaceutical industry, Halozyme has established strategic partnerships with major pharmaceutical companies, significantly expanding its market reach. Notable achievements include the successful integration of its technology into various therapeutic areas, including oncology and diabetes care. As a pioneer in the field, Halozyme continues to drive advancements in drug delivery, positioning itself as a key player in the evolving landscape of biotechnology.

DitchCarbon Score

How does Halozyme Therapeutics, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.

20

Industry Average

Mean score of companies in the Health Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.

19

Industry Benchmark

Halozyme Therapeutics, Inc.'s score of 20 is lower than 78% of the industry. This can give you a sense of how well the company is doing compared to its peers.

22%

Let us know if this data was useful to you

Halozyme Therapeutics, Inc.'s reported carbon emissions

In 2023, Halozyme Therapeutics, Inc., headquartered in the US, reported total carbon emissions of approximately 2,318,717 kg CO2e. This figure includes about 1,460,784 kg CO2e from Scope 1 emissions and approximately 862,933 kg CO2e from Scope 2 emissions. Currently, there are no disclosed Scope 3 emissions data. Despite the absence of specific reduction targets or initiatives, Halozyme is committed to addressing its carbon footprint. The company has not outlined any formal climate pledges or science-based targets for emissions reduction. As the biopharmaceutical industry increasingly focuses on sustainability, Halozyme's ongoing efforts to monitor and manage its emissions will be crucial in aligning with broader climate commitments.

Unlock detailed emissions data

Access structured emissions data, company-specific emission factors, and source documents

2023
Scope 1
1,460,784.25
Scope 2
862,932.72
Scope 3
-

Industry emissions intensity

Very low
Low
Medium
High
Very high
Some industries are more carbon intensive than others. Halozyme Therapeutics, Inc.'s primary industry is Health and social work services (85), which is low in terms of carbon intensity compared to other industries.

Location emissions intensity

Very low
Low
Medium
High
Very high
The carbon intensity of the energy grid powering a company's primary operations has a strong influence on its overall carbon footprint. This request for Halozyme Therapeutics, Inc. is in US, which has a low grid carbon intensity relative to other regions.

Reduction initiatives & disclosure networks

Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.

Halozyme Therapeutics, Inc. is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.

Science Based Targets Initiative
Carbon Disclosure Project
The Climate Pledge
UN Global Compact
RE 100
Climate Action 100
Race To Net Zero
Reduction Actions

Similar Organizations

West Pharmaceutical Services

US
Medical, precision and optical instruments, watches and clocks (33)
Updated about 24 hours ago

Phastar

GB
Pharmaceutical Preparation Manufacturing
Updated 1 day ago

Accord Healthcare, Inc.

US
Pharmaceutical Preparation Manufacturing
Updated 1 day ago

Veradigm

US
Computer and related services (72)
Updated 1 day ago

Marqeta, Inc.

US
Computer and related services (72)
Updated 1 day ago

Mr. Cooper Group Inc.

US
Financial intermediation services, except insurance and pension funding services (65)
Updated 1 day ago

Where does DitchCarbon data come from?

Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers